To assess the payer-rated value of improved pain response, reduced analgesic medication use and increased overall survival treatment benefit, for patients with castration-resistant prostate cancer (CRPC). METHODS: We used a convenience sample of payers in the US, France and Italy to conduct a telephone survey with an accompanying web-based questionnaire. The concern of the survey was the value to payers of a clinically significant pain response. The web-based questionnaire included nine different treatment/outcome scenarios associated with adding a second-generation antisense oligonucleotide (ASO) (product X) to standard of care (SOC) for patients with CRPC. Scenarios varied in terms of the percentage of patients who experienced a significant pain response with a concurrent specified reduction in pain medication use and survival benefit. For each scenario, the respondents rated their likelihood to recommend product X on a scale ranged from 1 (definitely would not) through 4 (definitely would). We analyzed quantitative scenario responses through use of linear regression methods; qualitative data analysis was limited to simple item summaries. RESULTS: A total of 36 payers in the U.S., France and Italy completed the survey and questionnaire. The qualitative data from all three regions showed improved survival drove affirmative recommendations for product X added to SOC. Informants from France and Italy also consistently ranked improved pain response as an important product attribute. The informants also said they would like more evidence regarding cost offsets associated with the improved pain response of product X plus SOC. The regression modeling was consistent with the qualitative observations. CONCLUSIONS: Coverage recommendations for the medical management of CRPC are primarily based on the amount of overall survival treatment benefit. In addition, most payers recognize increased pain response as an important attribute and said evidence of the cost offsets associated with pain response would aid decision making. 
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OBJECTIVES:
Overall Survival (OS) has generally been considered the "gold standard endpoint" for cancer therapies as it can be assessed with precise accuracy. Due to long follow up periods, however, crossover effects, subsequent therapies and large trial sizes, OS is becoming a less feasible endpoint. Therefore, there has been a shift towards the acceptance of surrogate endpoints as determinants of clinical efficacy for cancer therapies. In Canada, the iJODR conducts health technology assessments for oncology products and provides funding recommendations to public payers. This study was conducted to determine the significance of various endpoints on decision-making by the iJODR. METHODS: Public recommendations of 23 oncology drugs by the iJODR between March 2007 and December 2010 were reviewed. Recommendations were analyzed according to therapy setting, primary and secondary endpoints and clinical results. RESULTS: Of the 23 submissions, one was for use in the adjuvant setting, measuring Disease Free Survival (DFS) as its primary endpoint and received a positive recommendation. Of the 22 drugs indicated for advanced/metastatic disease, primary endpoints were measured in 12 (55%) through OS, 5 (18%) through Progression Free Survival (PFS) and 6 (27%) through either Response Rates (RR) or Time to Progression (TTP). Secondary endpoints included OS, PFS, toxicity, RR, TTP, Quality of Life or Rate of Progression. Of the 12 drugs with OS as a primary endpoint, 7 (58%) showed statistically significant increases in OS, with 4 (57%) granted a positive recommendation. Of the 5 with no statistically significant OS improvement, 3 (60%) received positive recommendations based on secondary endpoints. Of the 10 drugs with surrogate primary endpoints, 6 (60%) received positive recommendations. CONCLUSIONS: These findings suggest that surrogate endpoints are becoming more commonly used in clinical trials for regulatory approval and accepted as true measures of clinical efficacy for oncology therapies in Canada's funding decisions. ) following 2 prostate cancer diagnoses (ICD-9: 185, V10.46) within 365 days were identified. Patients with other malignant diagnoses at baseline, defined as 365 days prior to metastasis diagnosis (index date), were excluded. Patients were evaluated for baseline medical history, and for chemotherapy, hormonal agents, radiation, and corticosteroids utilization during both baseline and observation periods. Hospitalization rates and prostate cancer-related procedures post index date were also reported. RESULTS: The study population comprised 11,725 patients (E: 3,227; M: 8,498). Mean age (SD) was 72.8 (10.2) in Employer and 78.1 (7.7) in Medicare. Mean observation period (SD) was 803 (753) days in Employer and 9.2 (8.2) quarters in Medicare. During the baseline period, chemotherapy, hormonal agents, radiation therapy, and corticosteroids were administered to 5%, 52%, 9%, and 21% of Employer, and 2%, 45%, 8%, and 12% of Medicare patients respectively, whereas these interventions increased to 22%, 55%, 39%, and 46% for Employer, and to 21%, 50%, 33%, and 29% for Medicare during the observation period. A total of 66% Employer and 79% Medicare patients were hospitalized post index date. Most patients (E: 92%; M: 98%) had prostate cancer-related procedures, including prostate specific-antigen testing (E: 39%; M: 80%), computerized axial tomography scan (E: 72%; M: 81%), prostate biopsy (E: 47%; M: 54%), X-ray (E: 11%; M: 64%), bone scan (E: 56%; M: 60%), and magnetic resonance imaging scan (E: 35%; M: 37%). CONCLUSIONS: This observational study describes realworld utilization patterns in patients with advanced prostate cancer.
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PCN111 ANALYSIS OF HEALTH OUTCOMES IN BREAST CANCER PATIENTS USING CLUSTER ANALYSIS
Ugiliweneza B University of Louisville, Louisville, KY, USA
OBJECTIVES:
The main objective is to define clusters of patient diagnoses and to use them to analyze breast cancer health outcomes. METHODS: The NIS records of 2005 were used. Patients diagnosed with breast cancer were extracted, and then clusters of strings of all diagnoses per hospitalization were defined. Logistic regression models were used to determine the risk of dying from hospitalization associated with each cluster and ANOVA models were used to evaluate the effect of diagnosis clusters on length of stay. Time series models were used to fit the data and predict one month of total charges and the number of hospitalizations for each cluster. The analysis was performed with SAS, SAS Enterprise Guide (EG), SAS Enterprise Miner (EM), and the SAS Time Series Forecasting System. RESULTS: Four clusters were found. These clusters had a significant effect on length of stay and in-hospital death. The best time series models were found to be the mean, linear trend and log linear trend. The cluster defined by breast cancer with internal body organ failure was found to be the worst condition with a longer in-hospital stay and a higher risk of in-hospital death. The one month predicted values for this cluster were found to be 942 hospitalizations and about $26 million in total charges. CONCLUSIONS: Cluster analysis is a useful method to study health outcomes. Enterprise Miner is an effective software for cluster analysis and Data Mining in general. 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
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